Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roelf Valkema

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Measuring Total Metabolic Tumor Volume from <sup>18</sup>F-FDG PET: A Reality CheckRonald Boellaard, Gerben J C Zwezerijnen, Irène Buvat, et al.
Leukemia|October 14, 2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAPJulia Driessen, Marie José Kersten, Lydia Visser, et al.
BMC Cancer|March 8, 2020
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort studyXiaobin Zhang, Ben M Eyck, Yang Yang, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Annals of Surgical Oncology|July 27, 2024
Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort StudyCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
BMC Cancer|February 8, 2018
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, et al.
Annals of Surgery|October 9, 2019
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched StudyBerend J van der Wilk, Bo J Noordman, Lisanne K A Neijenhuis, et al.
Trials|May 18, 2021
Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancerBen M Eyck, Berend J van der Wilk, Bo Jan Noordman, et al.
The Lancet. Oncology|March 20, 2025
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialBerend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, et al.
The British Journal of Surgery|January 27, 2026
Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial)Sanjiv S G Gangaram Panday, Berend J van der Wilk, Ben M Eyck, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Measuring Total Metabolic Tumor Volume from <sup>18</sup>F-FDG PET: A Reality CheckRonald Boellaard, Gerben J C Zwezerijnen, Irène Buvat, et al.
Leukemia|October 14, 2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAPJulia Driessen, Marie José Kersten, Lydia Visser, et al.
BMC Cancer|March 8, 2020
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort studyXiaobin Zhang, Ben M Eyck, Yang Yang, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Annals of Surgical Oncology|July 27, 2024
Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort StudyCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
BMC Cancer|February 8, 2018
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, et al.
Annals of Surgery|October 9, 2019
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched StudyBerend J van der Wilk, Bo J Noordman, Lisanne K A Neijenhuis, et al.
Trials|May 18, 2021
Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancerBen M Eyck, Berend J van der Wilk, Bo Jan Noordman, et al.
The Lancet. Oncology|March 20, 2025
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialBerend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, et al.
The British Journal of Surgery|January 27, 2026
Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial)Sanjiv S G Gangaram Panday, Berend J van der Wilk, Ben M Eyck, et al.
Pageof 10